SPS2, for example, exploits the Se dependency of certain cancers, such as breast cancer, lymphoma, and melanoma by disrupting selenoprotein synthesis and inducing toxic selenide accumulation, which selectively targets cancer cells without affecting normal cells [71]. This evidence concerns the gene SEPHS2 and melanoma.